Author:
Keshishi Dro,Makunts Tigran,Abagyan Ruben
Abstract
AbstractOsteoporosis affects over 10 million Americans over 50. Bisphosphonate therapy, mainly alendronate, is amongst the most prescribed treatments for the disease. The use of alendronate and other bisphosphonates has been associated with depressive symptoms in recent case reports. In this study we quantified this association by analyzing over 100,000 adverse events reports from the Food and Drug Administration Adverse Events Reporting System (FAERS) and the World Health Organization’s (WHO) global database for adverse drug reactions, ADRs, VigiAccess. We found that alendronate therapy is significantly associated with depression and anxiety when compared to other first-line osteoporosis treatments. The reported risk of depressive ADRs was found to be over 14-fold greater in patients taking alendronate under the age of 65 and over fourfold greater for patients over 65 compared to the control. Several hypotheses concerning the molecular mechanism of the observed association of alendronate and depressive symptoms were discussed.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. 54 Million Americans Affected by Osteoporosis and Low Bone Mass. National Osteoporosis Foundation https://www.nof.org/news/54-million-americans-affected-by-osteoporosis-and-low-bone-mass/.
2. Tu, K. N. et al. Osteoporosis: A review of treatment options. Pharm. Ther. 43, 92–104 (2018).
3. Reszka, A. A. & Rodan, G. A. Mechanism of action of bisphosphonates. Curr. Osteoporos. Rep. 1, 45–52 (2003).
4. Hanley, D. A., Adachi, J. D., Bell, A. & Brown, V. Denosumab: Mechanism of action and clinical outcomes. Int. J. Clin. Pract. 66, 1139–1146 (2012).
5. Bodenner, D., Redman, C. & Riggs, A. Teriparatide in the management of osteoporosis. Clin. Interv. Aging 2, 499–507 (2007).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献